Michael W. Dunne - Net Worth and Insider Trading
Michael W. Dunne Net Worth
The estimated net worth of Michael W. Dunne is at least $145,605 dollars as of 2024-11-05. Michael W. Dunne is the Director of Iterum Therapeutics PLC and owns about 113,754 shares of Iterum Therapeutics PLC (ITRM) stock worth over $145,605. Details can be seen in Michael W. Dunne's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Michael W. Dunne has not made any transactions after 2023-12-22 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Michael W. Dunne
Michael W. Dunne Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Michael W. Dunne owns 2 companies in total, including Iterum Therapeutics PLC (ITRM) , and Vaxart Inc (VXRT) .
Click here to see the complete history of Michael W. Dunne’s form 4 insider trades.
Insider Ownership Summary of Michael W. Dunne
Ticker | Comapny | Transaction Date | Type of Owner |
---|---|---|---|
ITRM | Iterum Therapeutics PLC | 2023-12-22 | Chief Scientific Officer |
VXRT | Vaxart Inc | 2015-09-21 | director |
Michael W. Dunne Latest Holdings Summary
Michael W. Dunne currently owns a total of 1 stock. Michael W. Dunne owns 113,754 shares of Iterum Therapeutics PLC (ITRM) as of December 22, 2023, with a value of $145,605.
Latest Holdings of Michael W. Dunne
Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
---|---|---|---|---|---|
ITRM | Iterum Therapeutics PLC | 2023-12-22 | 113,754 | 1.28 | 145,605 |
Holding Weightings of Michael W. Dunne
Michael W. Dunne Form 4 Trading Tracker
According to the SEC Form 4 filings, Michael W. Dunne has made a total of 5 transactions in Iterum Therapeutics PLC (ITRM) over the past 5 years, including 4 buys and 1 sells. The most-recent trade in Iterum Therapeutics PLC is the acquisition of 25,000 shares on December 22, 2023, which cost Michael W. Dunne around $35,000.
Insider Trading History of Michael W. Dunne
- 1
Michael W. Dunne Trading Performance
GuruFocus tracks the stock performance after each of Michael W. Dunne's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Michael W. Dunne is -21.25%. GuruFocus also compares Michael W. Dunne's trading performance to market benchmark return within the same time period. The performance of stocks bought by Michael W. Dunne within 3 months outperforms 1 times out of 7 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Michael W. Dunne's insider trading performs compared to the benchmark.
Performance of Michael W. Dunne
Michael W. Dunne Ownership Network
Ownership Network List of Michael W. Dunne
Ownership Network Relation of Michael W. Dunne
Michael W. Dunne Owned Company Details
What does Iterum Therapeutics PLC do?
Who are the key executives at Iterum Therapeutics PLC?
Michael W. Dunne is the Chief Scientific Officer of Iterum Therapeutics PLC. Other key executives at Iterum Therapeutics PLC include director & President & CEO Fishman Corey N. , Chief Medical Officer Sailaja Puttagunta , and Chief Financial Officer Judith M. Matthews .
Iterum Therapeutics PLC (ITRM) Insider Trades Summary
Over the past 18 months, Michael W. Dunne made 3 insider transaction in Iterum Therapeutics PLC (ITRM) with a net purchase of 55,000. Other recent insider transactions involving Iterum Therapeutics PLC (ITRM) include a net purchase of 10,000 shares made by Fishman Corey N. ,
In summary, during the past 3 months, insiders sold 0 shares of Iterum Therapeutics PLC (ITRM) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Iterum Therapeutics PLC (ITRM) were sold and 65,000 shares were bought by its insiders, resulting in a net purchase of 65,000 shares.
Iterum Therapeutics PLC (ITRM)'s detailed insider trading history can be found in Insider Trading Tracker table.
Iterum Therapeutics PLC Insider Transactions
Michael W. Dunne Mailing Address
Above is the net worth, insider trading, and ownership report for Michael W. Dunne. You might contact Michael W. Dunne via mailing address: Durata Therapeutics, Inc., 89 Headquarters Plaza North, 14th Floor, Morristown Nj 07960.